Analysts’ updated eps estimates for Monday, March 17th:
Akebia Therapeutics (NASDAQ:AKBA) was upgraded by analysts at StockNews.com from a sell rating to a hold rating.
StockNews.com started coverage on shares of Applied DNA Sciences (NASDAQ:APDN). The firm issued a sell rating on the stock.
Avino Silver & Gold Mines (NYSE:ASM) was upgraded by analysts at StockNews.com from a hold rating to a buy rating.
Perspective Therapeutics (NYSE:CATX) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $11.00 target price on the stock.
Chunghwa Telecom (NYSE:CHT) was upgraded by analysts at StockNews.com from a hold rating to a buy rating.
Sanford C. Bernstein assumed coverage on shares of Coinbase Global (NASDAQ:COIN). Sanford C. Bernstein issued an outperform rating and a $310.00 target price on the stock.
Citizens Community Bancorp (NASDAQ:CZWI) was upgraded by analysts at StockNews.com from a hold rating to a buy rating.
Fresh Del Monte Produce (NYSE:FDP) was upgraded by analysts at StockNews.com from a hold rating to a buy rating.
Flushing Financial (NASDAQ:FFIC) was upgraded by analysts at StockNews.com from a sell rating to a hold rating.
Futu (NASDAQ:FUTU) had its target price raised by UBS Group AG from $130.00 to $136.00. UBS Group AG currently has a buy rating on the stock.
Hexcel (NYSE:HXL) was upgraded by analysts at StockNews.com from a hold rating to a buy rating.
iRobot (NASDAQ:IRBT) was upgraded by analysts at StockNews.com from a sell rating to a hold rating.
Pagaya Technologies (NASDAQ:PGY) had its buy rating reiterated by analysts at B. Riley. They currently have a $36.00 price target on the stock.
Scholar Rock (NASDAQ:SRRK) had its outperform rating reaffirmed by analysts at Wedbush. The firm currently has a $50.00 target price on the stock.
Tesla (NASDAQ:TSLA) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. The firm currently has a $404.00 price target on the stock.
Wheaton Precious Metals (NYSE:WPM) had its target price increased by Scotiabank from $78.00 to $79.00. Scotiabank currently has a sector outperform rating on the stock.
Receive News & Ratings for Akebia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.